Uses and limitations of bone material density measurements in the management of osteoporosis

MedGenMed Medscape General Medicine

Volumn 7, Issue 2, 2005, Pages

  Small, Ralph E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCIUM; ESTROGEN; ETIDRONIC ACID; FLUORIDE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; TILUDRONIC ACID; VITAMIN D;

ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE STRENGTH; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LUMBAR SPINE; MEDICAL DECISION MAKING; META ANALYSIS; OSTEOPOROSIS; PATIENT MONITORING; RISK REDUCTION; SYSTEMATIC REVIEW; VERTEBRA FRACTURE; BONE MINERALIZATION; INJURY; LUMBAR VERTEBRA; METHODOLOGY; PROGNOSIS; RADIODENSITOMETRY; RADIOGRAPHY; REPRODUCIBILITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SPINE FRACTURE; STATISTICS;

CALCIFICATION, PHYSIOLOGIC; DENSITOMETRY, X-RAY; HUMANS; LUMBAR VERTEBRAE; OSTEOPOROSIS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SPINAL FRACTURES;

EID: 25144435400     PISSN: None     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Division of Metabolic and Endocrine Drug Products. Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Available at: http://www.fda.gov/cder/guidance/osteo.pdf Accessed April 24, 2005.
2. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112:281-289.
3. Watts NB, Cooper C, Lindsay R, et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom. 2004;7:255-261.
4. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-795.
5. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2003.
6. National Osteoporosis Foundation. America's Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation. Washington, DC: National Osteoporosis Foundation; 2002.
7. Cuddihy MT, Gabriel SE, Crowson CS, et al. Osteoporosis intervention following distal forearm fractures: a missed opportunity? Arch Intern Med. 2002;162:421-426.
8. Finkelstein JS. Osteoporosis. In: Cecil RL, Goldman L, Bennett JC, eds. Cecil Textbook of Medicine. 21st ed. Philadelphia, Pa: WB Saunders Co.; 2000:1367-1373.
9. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129.
10. Leib ES, Lewiecki EM, Binkley N, Hamdy RC. Official positions of the international society for clinical densitometry. J Clin Densitom. 2004;7:1-6.
11. Miller PD, Zapalowski C, Kulak CA, Bilezikian JP. Bone densitometry: the best way to detect osteoporosis and to monitor therapy. J Clin Endocrinol Metab. 1999;84:1867-1871.
12. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet. 1993;341:72-75.
13. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254-1259.
14. Wainwright S, Phipps K, Stone J, et al. A large proportion of fractures in postmenopausal women occur with baseline bone mineral density T-score -2.5. J Bone Miner Res. 2001;16:S155.
15. Luengo M, Picado C, Del Rio L, et al. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax. 1991;46:803-806.
16. Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 2001;86:32-38.
17. American College of Obstetricians and Gynecologists, Women's Health Care Physicians. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 50, January 2003. Obstet Gynecol. 2004;103:203-216.
18. U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med. 2002;137:526-528.
19. Mundy GR. Bone remodeling. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Philadelphia, Pa: Lippincott Williams & Wilkins; 1999:30-38.
20. Parfitt AM, Mathews CH, Villanueva AR, et al. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. J Clin Invest. 1983;72:1396-1409.
21. Kleerekoper M, Villanueva AR, Stanciu J, Rao DS, Parfitt AM. The role of three-dimensional trabecular microstructure in the pathogenesis of vertebral compression fractures. Calcif Tissue Int. 1985;37:594-597.
22. Ammann P, Rizzoli R. Bone strength and its determinants. Osteoporos Int. 2003;14(suppl3):S13-S18.
23. Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003;18:1051-1056.
24. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344-1352.
25. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11:83-91.
26. Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within 6 months. Curr Med Res Opin. 2004;20:433-439.
27. Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;74:129-135.
28. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000;85:4118-4124.
29. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637-645.
30. Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000;109:267-276.
31. Meunier PJ, Sebert JL, Reginster JY, et al. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVO Study. Osteoporos Int. 1998;8:4-12.
32. Pak CY, Zerwekh JE, Antich P. Anabolic effects of fluoride on bone. Trends Endocrinol Metab. 1995;6:229-234.
33. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441.
34. Dempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res. 2001;16:1846-1853.
35. Dufresne TE, Chmielewski PA, Manhart MD, Johnson TD, Borah B. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int. 2003;73:423-432.
36. Roschger P, Rinnerthaler S, Yates J, et al. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone. 2001;29:185-191.
37. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab. 2000;85:231-236.
38. Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002;87:1586-1592.
39. Sarkar S, Mitlak BH, Wong M, et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002;17:1-10.
40. Watts NB, Felsenberg D, Johnson TD, Li Z, Eastell R. Small proportion of nonvertebral fracture risk reduction explained by BMD increases [abstract P2-487]. Paper presented at: The Endocrine Society's 85th Annual Meeting; June 19-22, 2003; Philadelphia, Pennsylvania.
41. Cummings S, Black D, Pearson J, et al. How much of the reduction in risk of vertebral fractures by alendronate is explained by increased spine BMD? [Abstract]. J Bone Miner Res. 1999;14:S159.
42. Cummings SR, Black DM, Vogt TM; FIT Research Group. Changes in BMD substantially underestimate the anti-fracture effects of alendronate and other antiresorptive drugs [abstract 29]. J Bone Miner Res. 1996;11:S102.
43. Li Z, Meredith M, Hoseyni MS. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med. 2001;20:3175-3188.